Related Experiment Video
Updated: Jan 2, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.4K
Tildrakizumab for Moderate-to-Severe Plaque Psoriasis
Uyen Ngoc Mui1, Ravi R Patel1, Ramya Vangipuram2
1Center for Clinical Studies, Houston, TX, USA
Skin Therapy Letter
|December 5, 2019
Summary
Psoriasis is an inflammatory skin disease driven by cytokines. New biologic therapies targeting interleukin-23 (IL-23), specifically IL-23p19 antagonists like tildrakizumab, offer improved safety and efficacy for patients.
Area of Science:
- Immunodermatology
- Inflammatory skin diseases
- Biologic therapies
Background:
- Psoriasis is a complex immune-mediated inflammatory skin condition impacting quality of life.
- Its pathogenesis involves proinflammatory cytokines, notably interleukin-23 (IL-23).
- Existing biologics target TNF, IL-17, IL-12, and IL-23, with IL-23 emerging as a key driver.
Purpose of the Study:
- To review the safety and efficacy of tildrakizumab.
- To highlight tildrakizumab as a novel IL-23p19 antagonist for psoriasis treatment.
Main Methods:
- Review of clinical trial data and scientific literature.
- Focus on tildrakizumab, a monoclonal antibody targeting the IL-23p19 subunit.
Main Results:
- IL-23p19 antagonists represent a new class of biologics for psoriasis.
- Tildrakizumab demonstrates a favorable safety and efficacy profile.
Conclusions:
- Targeting IL-23p19 with tildrakizumab is a promising therapeutic strategy for psoriasis.
- Further research supports the role of IL-23 in psoriasis pathogenesis and treatment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
408
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
408
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
424
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
424
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
376
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
376
01:29Drugs for Treatment of Ulcerative Colitis in IBD
398
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
398
01:26Psychosis: Goals of Pharmacotherapy
414
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
414
01:29Inflammatory Bowel Disease IV: Pharmacological Management
413
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
413